-GAAP adjusted net income for the three months ended March 31, 2013 was $11 million, compared to $31 million for the same period in 2012. Non-GAAP adjusted diluted net earnings per share was $0.15 for the first quarter of 2013 compared to $0.37 for the same period in 2012. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release.Operating Highlights
Cinryze net sales during the first quarter of 2013 were $99.5 million, a 46 percent increase over the same period in 2012 driven by demand growth, rebuilding channel inventories and net realized price growth. Vancocin net sales during the three months were $4 million compared to $66 million for the same period in 2012. The decrease is due to the impact of the launch of generic versions of vancomycin in April of 2012. During the first quarter of 2013, we generated net sales of approximately $7 million from our European operations.
Cost of sales decreased for the three months ended March 31, 2013 as compared to the three months ended March 31, 2012 by $2 million. The decrease in cost of sales was due to product mix and overall sales decline of Vancocin compared to the same period in the prior year. We anticipate that our cost of sales, on a relative basis, will remain higher than historical levels due to the introduction of generic vancomycin and the reduction of our sales of Vancocin relative to our Cinryze sales along with the royalty due to Genzyme on Vancocin-related sales.
Research and development costs incurred during the first quarter of 2013 increased compared to the same period in 2012 due to advancements in our clinical development programs, including the subcutaneous Cinryze and maribavir development programs, among others. The increase in selling, general and administrative expenses for the first quarter of 2013 compared to the same perio
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
|SOURCE ViroPharma Incorporated|
Copyright©2012 PR Newswire.
All rights reserved
. ViroPharma to Participate in Two December Healthcare Investor Conferences2
. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results3
. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting4
. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations5
. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference6
. ACORN Research, LLC Announces Partnership with AdeptBio, LLC7
. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results8
. WuXi PharmaTech Announces Third-Quarter 2011 Results9
. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting10
. Spherix Announces Third Quarter Financial Results11
. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition